

Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - L52310MH2008PLC181632

13th April, 2020

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Stock Code: VAISHALI

Dear Sir/Madam,

Sub: Press Release on receipt of Export Order.


We refer to captioned subject and with to inform that the Company has received orders for supply of various Antibiotics and other generic medicines along with Surgical Consumables of INR 100 Million from Russia, Nicaragua, Turkmenistan, Angola, Myanmar, Cambodia, Kenya and few more.

Please find enclosed herewith a copy of Press Release giving information about the same.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,
For Vaishali Pharma Limited


Atul Arvind Vasani
Managing Director



An ISO 9001:2015 & Crisil Certified Company

Website : www.vaishalipharma.com

April 13 2020

To
Corporate Relation Manager,
NSE, BKC.
Mumbai,

Reference: Received Export Order

Recently, Company has received the Orders for supply of various Antibiotics and other generic medicines along with Surgical Consumables of INR 100 Million from Russia, Nicaragua, Turkmenistan, Angola, Myanmar, Cambodia, Kenya and few more. We will try and deliver it as committed to help clientele to fight during COVID-19 pandemic. In such critical situation, we will supply all products and enables the Company to reach out more and strengthen its presence.

We are expecting a lot of demand for all medicines & consumables from all countries. Greater acceptance of Indian products as people all over World have valued the support shown by Indians during such precarious times. During these times when the government gives the green light to commence operations for Hydroxychloroquine and other products which seems to be helpful to fight against COVID for exports this will help us see many breaks and would try to support them as much as possible. We would help the Society overcome these difficult times together with our strengths.

About Vaishali Pharma Limited:

Vaishali Pharma Limited (NSE: VAISHALI), abided by the norms of extending uncompromised quality products, has raised the standards of the industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

Incorporated in the year 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 80 formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai, our offices are also located in Kenya, & Vietnam. Further widening our reach overseas, the Company made a joint venture with D.R. Congo based company. The Company exports to countries like Africa, Kenya, Myanmar, Vietnam, Russia etc.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

Current COVID Situation:

While the COVID 19 pandemic is rapidly evolving, Vaishali's management continues to monitor the situation closely and take measures to maintain business continuity without compromising the safety of its employees in any way.

We strictly follow the instructions given by the Central as well as the State Governments in this regard from time to time. Our employees have been permitted to work from home ever-since the announcement of lock down. All business reviews and discussions are conducted through video/audio conferencing facilities.

These are unprecedented times. We strongly believe that our asset light model will help us come out of this pandemic with a position of strength. Exposure to 25 and more countries with wide range of portfolio covering from Generic medicines to consumables products proves to be beneficial and help us business continuity.

Management Comment:

Commenting on the recent development, Mr. Atul Vasani, Managing Director, Vaishali Pharma Limited said:

We are supporting our communities across the globe. All of our employees around the world have been strongly encouraged to work from home. We're also trying to make most of the products available for our customers, partners and communities.

We sincerely hope that the current crisis resolves at the earliest and pray for the wellbeing of our stakeholders, distributors and other business partner

For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Mr. Atul Vasani

Managing Director

Vaishali Pharma Limited

Email: director@vaishalipharma.com

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*